129 related articles for article (PubMed ID: 38373843)
1. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers JO; Genre F; Hiepe F; Gerosa M; Kovács L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; ; Alarcón-Riquelme ME; Beretta L
Ann Rheum Dis; 2024 Jun; 83(7):889-900. PubMed ID: 38373843
[TBL] [Abstract][Full Text] [Related]
2. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
Pawlak-Buś K; Schmidt W; Leszczyński P
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
[TBL] [Abstract][Full Text] [Related]
3. [Low disease activity and remission status of systemic lupus erythematosus in a real-world study].
Ren L; Zhao C; Zhao Y; Zhou H; Zhang L; Wang Y; Shen L; Fan W; Li Y; Li X; Wang J; Cheng Y; Peng J; Zhao X; Shao M; Li R
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):273-278. PubMed ID: 38595244
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
[TBL] [Abstract][Full Text] [Related]
5. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
[TBL] [Abstract][Full Text] [Related]
6. Targeting DORIS Remission and LLDAS in SLE: A Review.
Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
[TBL] [Abstract][Full Text] [Related]
7. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
[TBL] [Abstract][Full Text] [Related]
8. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
9. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
[TBL] [Abstract][Full Text] [Related]
10. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.
Samões B; Zen M; Abelha-Aleixo J; Gatto M; Doria A
Autoimmun Rev; 2022 Oct; 21(10):103165. PubMed ID: 35931316
[TBL] [Abstract][Full Text] [Related]
11. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Morand EF; Abreu G; Furie RA; Golder V; Tummala R
Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
[TBL] [Abstract][Full Text] [Related]
12. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Lofland J; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus.
Thibault T; Rajillah A; Bourredjem A; Corneloup M; Maurier F; Wahl D; Muller G; Aumaitre O; Sève P; Blaison G; Besancenot JF; Martin T; Magy-Bertrand N; Samson M; Arnaud L; Amoura Z; Devilliers H;
Rheumatology (Oxford); 2024 May; 63(5):1447-1455. PubMed ID: 37589711
[TBL] [Abstract][Full Text] [Related]
14. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus.
Smith EMD; Tharmaratnam K; Al-Abadi E; Armon K; Bailey K; Brennan M; Ciurtin C; Gardner-Medwin J; Haslam KE; Hawley D; Leahy A; Leone V; Malik G; McLaren Z; Pilkington C; Ramanan AV; Rangaraj S; Ratcliffe A; Riley P; Sen E; Sridhar A; Wilkinson N; Hedrich CM; Jorgensen A; Beresford MW
Rheumatology (Oxford); 2022 Aug; 61(8):3378-3389. PubMed ID: 34894234
[TBL] [Abstract][Full Text] [Related]
15. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
Altabás-González I; Rúa-Figueroa I; Rubiño F; Mouriño Rodríguez C; Hernández-Rodríguez I; Menor Almagro R; Uriarte Isacelaya E; Tomero Muriel E; Salman-Monte TC; Carrión-Barberà I; Galindo M; Rodríguez Almaraz EM; Jiménez N; Inês L; Pego-Reigosa JM
Rheumatology (Oxford); 2023 Mar; 62(3):1162-1169. PubMed ID: 35961050
[TBL] [Abstract][Full Text] [Related]
16. Remission in SLE-do DORIS criteria match the treating physician's judgment? A cross-sectional study to assess reasons for discordance.
Mucke J; Düsing C; Klose N; Schneider M; Chehab G
Rheumatology (Oxford); 2021 Sep; 60(9):4298-4305. PubMed ID: 33493321
[TBL] [Abstract][Full Text] [Related]
17. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
[TBL] [Abstract][Full Text] [Related]
18. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
[TBL] [Abstract][Full Text] [Related]
19. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
[TBL] [Abstract][Full Text] [Related]
20. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
